The latest episode of Trade To Black, presented by Flowhub, packed three distinct conversations into one hour: a skeptical read on a new bipartisan hemp bill, a wide-ranging interview with Flowhub Founder and CEO Kyle Sherman on cannabis retail technology, and a clinical discussion with Dr. Paul Shields on CBD dosing gaps. Hosts Shadd Dales and Anthony Varrell opened with the policy story, then moved into operations and product science - a format that mirrors how operators actually have to think, since regulation, technology, and product formulation are never really separate problems.
On the legislative front, Reps. Andy Barr and Angie Craig introduced the Lawful Hemp Protection Act, which would set a 1% total-THC threshold on finished products, restrict sales to adults 21 and older, ban synthetic conversions such as Delta-8 and THCP, and impose national testing, labeling, and an alcohol-style three-tier distribution structure, plus a federal retail and THC tax. Dales and Varrell were not convinced it moves fast enough to attach to a continuing resolution or head off the November 12 hemp ban, and they restated a position they've held for a while: full-spectrum cannabis products, hemp-derived or not, belong under one rescheduled, state-regulated system rather than two competing regulatory tracks. That argument matters for retailers licensed under state adult-use and medical programs, many of whom already run a cannabis POS for Colorado dispensaries alongside compliance tools built for METRC reporting, and who watch federal hemp policy nervously because it directly affects what competing products show up on gas station shelves down the street. cannabis POS for Colorado dispensaries
Sherman on Open Systems and the Limits of All-in-One Software
Sherman's segment centered on a familiar operator headache: dispensaries running separate systems for point-of-sale, e-commerce, payments, loyalty, compliance logging, and analytics, often stitched together with workarounds. His argument was that retailers should own their customer relationships, their data, their brand, and their choice of technology partners - not be locked into whatever roadmap a single vendor decides to prioritize. He walked through Flowhub's headless commerce product, Open Ecommerce, which lets operators build custom websites, apps, kiosks, and new ordering channels without tearing out the core POS and compliance backbone underneath. That's a meaningful distinction for multi-state operators managing SKU catalogs, wholesale menus, and delivery manifests across different state frameworks, where ripping and replacing a core system mid-operation is expensive and risky.
Sherman also addressed cashless payments directly, noting that credit-card acceptance may still be years away even if cannabis moves to Schedule III, since federal banking rules and card network policies don't automatically shift with a rescheduling decision. He predicted cannabis will eventually outgrow alcohol as a category as consumer habits tilt toward wellness-oriented use, and he cited Flowhub data showing 52% of cannabis retailers already using artificial intelligence, primarily for data analysis rather than customer-facing applications. For store operators, that's a reminder that AI adoption in this sector is running ahead of banking access - not exactly the sequencing anyone would have designed on purpose.
Shields on the Dosing Gap Retailers Can't Ignore
Dr. Shields tackled a roughly 50-year research gap on cannabis efficacy, arguing that later-stage clinical trials could move relatively quickly given the existing safety data already on record. His sharper point was about dosing: retail CBD products often sit well below the range where users report noticeable effects, with that threshold often starting near 50 milligrams and running to 150-300 for therapeutic use. The practical fallout is a familiar story on the retail floor - a customer tries an underdosed product once, feels nothing, and writes off the entire category, which is as much a manufacturing and labeling problem as a consumer education one.
Shields also flagged real interaction risks between cannabinoids and medications like blood thinners and antiepileptics, a point budtenders and compliance teams should treat as a genuine consumer-safety issue rather than a footnote. He expects the indica/sativa framing to fade in medical contexts as cannabinoid and terpene profiles get more precise attention, though he was careful to note that questions around terpenes and the entourage effect remain open research territory, not settled science. For dispensary operators building out COA-backed product education, that distinction between what's proven and what's still under study is worth keeping straight - for staff training and for staying on the right side of marketing rules.
